RECOMBINANT ENV AND GAG POLYPEPTIDES IN CHARACTERIZING HIV-1-NEUTRALIZING ANTIBODIES NLM AIDSLINE Important note: Information in this article was accurate in 1989. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


RECOMBINANT ENV AND GAG POLYPEPTIDES IN CHARACTERIZING HIV-1-NEUTRALIZING ANTIBODIES

Vaccines 88. New Chemical and Genetic Approaches to Vaccination: Prevention of AIDS and Other Viral, Bacterial, and Parasitic Diseases. Ginsberg H et al, eds. New York, Cold Spring Harbor Laboratory, p. 347-55, 1988.. Unique Identifier : AIDSLINE ICDB/89649780
Steimer KS; Van Nest GA; Haigwood NL; Tillson EM; George-Nascimento C; Barr PJ; Dina D; Chiron Corp., Emeryville, CA 94608

Abstract: The strain specificities of affinity-purified human antibodies and animal antisera to a nonglycosylated HIV-SF2 polypeptide representing the gp120 region of the env genes were examined, and efforts were made to identify the target(s) of the HIV-SF2-neutralizing antibodies that do not bind to this antigen. Neutralizing antibodies in HIV antibody-positive human sera were found to bind to env 2-3, a nonglycosylated polypeptide corresponding to the amino acid sequence of gp120, the large external glycoprotein of the HIV-SF2 isolate. However, there were also HIV-SF2-neutralizing antibodies that did not bind this antigen. Other recombinant antigens from the env and gag genes, produced in genetically engineered yeast, did not bind this second category of HIV-neutralizing antibodies. Human antibodies specific for env 2-3 cross-neutralized some, but not all, HIV isolates. Animal antisera raised to env 2-3 also exhibited restricted neutralization of HIV isolates. The majority of the cross-neutralizing activity of human sera is directed against as yet unidentified epitopes in env (eg, conformational epitopes) or other target molecules. Future studies will be directed toward identifying these target regions in order to elicit a humoral immune response that will be effective against all HIV strains. (22 Refs)
Keywords: Animal Antibody Specificity Epitopes/IMMUNOLOGY Human HIV Antibodies/*ANALYSIS HIV-2/*IMMUNOLOGY *Neutralization Tests Peptides/*IMMUNOLOGY Recombinant Proteins/*IMMUNOLOGY Retroviridae Proteins/*IMMUNOLOGY MEETING PAPER

KWDanimalantibodyspecificityepitopes/immunologyhumanhivantibodies/KWDanalysishiv-2/KWDimmunologyKWDneutralizationtestspeptides/KWDimmunologyrecombinantproteins/KWDimmunologyretroviridaeproteins/KWDimmunologymeetingpaper
890330
M8930526

Copyright © 1989 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1989. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1989. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .